Press release from Companies

Publicerat: 2021-10-21 10:00:00

DanCann Pharma A/S: DanCann Pharma A/S: Correction: Flagging announcement in DanCann Pharma A/S

Correction of the previously disclosed press release since the information is not regarded as insider information. The MAR-label has therefore been removed from the press release.

COPENHAGEN, Denmark, 21 October 2021, DanCann Pharma A/S ("DanCann" or the "Company"), a Danish company powered by cannabinoids, hereby announces that the shareholder Xignotus Capital ApS’ ("Xignotus") holding in the Company, as a result of the acquisition of CannGros ApS and the directed issue of units as of 05 October 2021 ("the Transactions"), has crossed the flagging limit of 25 percent.

Prior to the Transactions, Xignotus’ holding in DanCann Pharma amounted to 25.62 percent of the votes and capital. Following the Transactions, Xignotus has now 21.65 percent of the votes and capital in the Company. The flagging announcement is published when the holding is crossing 25 percent, in accordance with Spotlight Stock Market's flagging rules.

Xignotus Capital ApS is owned by the Company's founder and CEO, Jeppe Krog Rasmussen, who currently owns 5,747,023 shares out of all 26,551,018 shares in DanCann Pharma.


Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit:

For further information, please contact:

Jeppe Krog Rasmussen, CEO
Website: www.dancann.com

Läs mer hos Cision
Läs mer om DanCann Pharma A/S